{"id":"conivaptan","rwe":[{"pmid":"41603272","year":"2026","title":"Effects of arginine vasopressin deficiency on cardiac fibrosis in male Wistar rats.","finding":"","journal":"Physiological reports","studyType":"Clinical Study"},{"pmid":"41428316","year":"2025","title":"Exploration of the protein and pharmacological landscape of monkeypox virus treatment: from entry point to end point.","finding":"","journal":"Molecular diversity","studyType":"Clinical Study"},{"pmid":"41352711","year":"2026","title":"MEGF8-mediated GDF8 phosphorylation drives TGF-β hyperactivation in osteoarthritis cartilage degeneration: Mechanism and targeted intervention.","finding":"","journal":"Life sciences","studyType":"Clinical Study"},{"pmid":"41188237","year":"2025","title":"Structural insights into antagonist recognition by the vasopressin V2 receptor.","finding":"","journal":"Nature communications","studyType":"Clinical Study"},{"pmid":"41129740","year":"2025","title":"B(C(6)F(5))(3)-Catalyzed Direct Deoxygenative Alkenylation of Ketones with Pinacolborane.","finding":"","journal":"The Journal of organic chemistry","studyType":"Clinical Study"}],"tags":[{"label":"Vasopressin Receptor Antagonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Vasopressin V2 receptor","category":"target"},{"label":"AVPR2","category":"gene"},{"label":"AVPR1A","category":"gene"},{"label":"C03XA02","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Liquid","category":"form"},{"label":"Solution","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Hyponatremia","category":"indication"},{"label":"Cumberland","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Antidiuretic Hormone Receptor Antagonists","category":"pharmacology"},{"label":"Natriuretic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"drugInteractions":[{"url":"/drug/cyp3a4-substrates","drug":"CYP3A4 Substrates","action":"Avoid combination","effect":"may increase the serum concentration of CYP3A4 Substrates","source":"DrugCentral","drugSlug":"cyp3a4-substrates"},{"url":"/drug/cyp3a4-substrates","drug":"CYP3A4 Substrates","action":"Use caution","effect":"Strong CYP3A4 Inhibitors - CYP3A4 Substrates","source":"DrugCentral","drugSlug":"cyp3a4-substrates"},{"url":"/drug/alfentanil","drug":"alfentanil","action":"Monitor closely","effect":"May interact with Alfentanil","source":"DrugCentral","drugSlug":"alfentanil"},{"url":"/drug/alfuzosin","drug":"alfuzosin","action":"Avoid combination","effect":"May interact with Alfuzosin","source":"DrugCentral","drugSlug":"alfuzosin"},{"url":"/drug/boceprevir","drug":"boceprevir","action":"Avoid combination","effect":"May interact with Boceprevir","source":"DrugCentral","drugSlug":"boceprevir"},{"url":"/drug/fentanyl","drug":"fentanyl","action":"Monitor closely","effect":"May interact with Fentanyl","source":"DrugCentral","drugSlug":"fentanyl"},{"url":"/drug/indinavir","drug":"indinavir","action":"Avoid combination","effect":"May interact with Indinavir Sulfate","source":"DrugCentral","drugSlug":"indinavir"},{"url":"/drug/itraconazole","drug":"itraconazole","action":"Avoid combination","effect":"May interact with Itraconazole","source":"DrugCentral","drugSlug":"itraconazole"},{"url":"/drug/ketoconazole","drug":"ketoconazole","action":"Avoid combination","effect":"May interact with Ketoconazole","source":"DrugCentral","drugSlug":"ketoconazole"},{"url":"/drug/lovastatin","drug":"lovastatin","action":"Avoid combination","effect":"May interact with Lovastatin","source":"DrugCentral","drugSlug":"lovastatin"},{"url":"/drug/mibefradil","drug":"mibefradil","action":"Avoid combination","effect":"May interact with Mibefradil Dihydrochloride","source":"DrugCentral","drugSlug":"mibefradil"},{"url":"/drug/nefazodone","drug":"nefazodone","action":"Avoid combination","effect":"May interact with Nefazodone","source":"DrugCentral","drugSlug":"nefazodone"},{"url":"/drug/oxycodone","drug":"oxycodone","action":"Monitor closely","effect":"May interact with Oxycodone","source":"DrugCentral","drugSlug":"oxycodone"},{"url":"/drug/posaconazole","drug":"posaconazole","action":"Avoid combination","effect":"May interact with Posaconazole","source":"DrugCentral","drugSlug":"posaconazole"},{"url":"/drug/ritonavir","drug":"ritonavir","action":"Avoid combination","effect":"May interact with Ritonavir","source":"DrugCentral","drugSlug":"ritonavir"},{"url":"/drug/silodosin","drug":"silodosin","action":"Avoid combination","effect":"May interact with Silodosin","source":"DrugCentral","drugSlug":"silodosin"},{"url":"/drug/simvastatin","drug":"simvastatin","action":"Avoid combination","effect":"May interact with Simvastatin","source":"DrugCentral","drugSlug":"simvastatin"},{"url":"/drug/tamsulosin","drug":"tamsulosin","action":"Avoid combination","effect":"May interact with Tamsulosin Hydrochloride","source":"DrugCentral","drugSlug":"tamsulosin"},{"url":"/drug/telaprevir","drug":"telaprevir","action":"Avoid combination","effect":"May interact with Telaprevir","source":"DrugCentral","drugSlug":"telaprevir"},{"url":"/drug/voriconazole","drug":"voriconazole","action":"Avoid combination","effect":"May interact with Voriconazole","source":"DrugCentral","drugSlug":"voriconazole"}],"commonSideEffects":[],"contraindications":["Acute nephropathy","Anuria","Chronic heart failure","Demyelination","Disease of liver","Hypernatremia","Hypovolemia","Kidney disease","Osmotic Central Pontine Myelinolysis"],"specialPopulations":{"Pregnancy":"VAPRISOL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The patient should be apprised of the potential hazard to the fetus. Conivaptan crosses the placenta.","Geriatric use":"In general, the adverse event profile in elderly patients was similar to that seen in the general study population.","Paediatric use":"The safety and effectiveness of VAPRISOL in pediatric patients have not been studied.","Renal impairment":"VAPRISOL is not recommended for severe renal impairment."}},"trials":[],"aliases":[],"company":"Cumberland","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CONIVAPTAN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:46:55.327846+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:47:00.697167+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CONIVAPTAN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:47:01.036273+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1755/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:47:01.760407+00:00"}},"allNames":"vaprisol in 5% dextrose in plastic container","offLabel":[],"synonyms":["conivaptan","conivaptan hydrochloride","vaprisol","YM-087","conivaptan HCl"],"timeline":[{"date":"2005-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from CUMBERLAND PHARMS to Cumberland"},{"date":"2005-12-29","type":"positive","source":"DrugCentral","milestone":"FDA approval (Cumberland Pharms)"}],"aiSummary":"Conivaptan, marketed as Vaprisol, is a vasopressin receptor antagonist developed by Cumberland Pharms. It targets the vasopressin V2 receptor to treat hyponatremia, a condition characterized by low sodium levels in the blood. Conivaptan is a small molecule modality with a half-life of 6.7 hours and bioavailability of 42%. As an off-patent medication, it is no longer protected by active patents, allowing generic manufacturers to produce the drug. Conivaptan is administered via a 5% dextrose solution in a plastic container.","approvals":[{"date":"2005-12-29","orphan":false,"company":"CUMBERLAND PHARMS","regulator":"FDA"}],"brandName":"Vaprisol In 5% Dextrose In Plastic Container","ecosystem":[{"indication":"Hyponatremia","otherDrugs":[{"name":"tolvaptan","slug":"tolvaptan","company":"Otsuka America Pharm"}],"globalPrevalence":null}],"mechanism":{"target":"Vasopressin V2 receptor","novelty":"Follow-on","targets":[{"gene":"AVPR2","source":"DrugCentral","target":"Vasopressin V2 receptor","protein":"Vasopressin V2 receptor"},{"gene":"AVPR1A","source":"DrugCentral","target":"Vasopressin V1a receptor","protein":"Vasopressin V1a receptor"}],"moaClass":"Cytochrome P450 3A Inhibitors","modality":"Small Molecule","drugClass":"Vasopressin Receptor Antagonist","explanation":"","oneSentence":"","technicalDetail":"Conivaptan selectively antagonizes the vasopressin V2 receptor, which is primarily responsible for water reabsorption in the kidneys, thereby increasing urine production and correcting hyponatremia."},"commercial":{"launchDate":"2005","_launchSource":"DrugCentral (FDA 2005-12-29, CUMBERLAND PHARMS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/732","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CONIVAPTAN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CONIVAPTAN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:17:40.124073","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:47:03.431047+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"tolvaptan","drugSlug":"tolvaptan","fdaApproval":"2009-05-19","patentExpiry":"Sep 1, 2026","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"conivaptan","indications":{"approved":[{"name":"Hyponatremia","source":"DrugCentral","snomedId":89627008,"regulator":"FDA","eligibility":{"Euvolemic Hyponatremia":"Hospitalized patients","Congestive Heart Failure":"Not indicated, but can be used in patients with underlying heart failure when the expected clinical benefit outweighs the risk of adverse events","Hypervolemic Hyponatremia":"Hospitalized patients"}}],"offLabel":[],"pipeline":[]},"currentOwner":"Cumberland","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"tolvaptan","brandName":"tolvaptan","genericName":"tolvaptan","approvalYear":"2009","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00727090","phase":"PHASE4","title":"Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2008-08","conditions":["Hyponatremia"],"enrollment":6,"completionDate":"2010-02"},{"nctId":"NCT03000283","phase":"PHASE1","title":"Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study","status":"COMPLETED","sponsor":"Jesse Corry","startDate":"2017-03-22","conditions":["Cerebral Hemorrhage","Cerebral Edema","Intracerebral Hemorrhage","Stroke"],"enrollment":7,"completionDate":"2019-04-15"},{"nctId":"NCT01954290","phase":"PHASE2","title":"Study of Stroke Related Edema Treatments","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2015-09","conditions":["Acute Cerebrovascular Accident","Cerebral Edema"],"enrollment":0,"completionDate":"2015-09"},{"nctId":"NCT01451411","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia","status":"TERMINATED","sponsor":"Cumberland Pharmaceuticals","startDate":"2012-02","conditions":["Hyponatremia"],"enrollment":4,"completionDate":"2014-01"},{"nctId":"NCT01752543","phase":"PHASE4","title":"Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients","status":"COMPLETED","sponsor":"Finn Gustafsson","startDate":"2013-12","conditions":["Heart Failure"],"enrollment":20,"completionDate":"2015-06"},{"nctId":"NCT00684164","phase":"PHASE3","title":"Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2008-05","conditions":["Hyponatremia"],"enrollment":0,"completionDate":"2010-06"},{"nctId":"NCT00478192","phase":"PHASE3","title":"Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2007-04","conditions":["Hyponatremia"],"enrollment":50,"completionDate":"2008-08"},{"nctId":"NCT00843986","phase":"PHASE3","title":"Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)","status":"TERMINATED","sponsor":"Cumberland Pharmaceuticals","startDate":"2009-04","conditions":["Hyponatremia","Acute Decompensated Heart Failure"],"enrollment":9,"completionDate":"2009-08"},{"nctId":"NCT00435591","phase":"PHASE4","title":"A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2007-01","conditions":["Hyponatremia","Euvolemia","Hypervolemia"],"enrollment":121,"completionDate":"2008-09"},{"nctId":"NCT00592475","phase":"PHASE2","title":"A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2007-12","conditions":["Liver Cirrhosis"],"enrollment":20,"completionDate":"2008-11"},{"nctId":"NCT00057356","phase":"PHASE2","title":"Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2002-11","conditions":["Chronic Heart Failure"],"enrollment":170,"completionDate":"2004-03"},{"nctId":"NCT01370148","phase":"PHASE1","title":"A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2011-04","conditions":["Liver Disease"],"enrollment":17,"completionDate":"2014-02"},{"nctId":"NCT00380575","phase":"PHASE3","title":"Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2000-08","conditions":["Hyponatremia"],"enrollment":84,"completionDate":"2003-02"},{"nctId":"NCT00379847","phase":"PHASE3","title":"An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2004-02","conditions":["Hyponatremia"],"enrollment":251,"completionDate":"2005-06"},{"nctId":"NCT00492037","phase":"PHASE3","title":"Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic Hyponatremia","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2000-01","conditions":["Hyponatremia"],"enrollment":83,"completionDate":"2002-02"},{"nctId":"NCT00851227","phase":"PHASE1","title":"Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2009-02","conditions":["Liver Disease","Hyponatremia"],"enrollment":26,"completionDate":"2010-01"},{"nctId":"NCT00887627","phase":"PHASE1","title":"Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2009-04","conditions":["Kidney Diseases","Hyponatremia"],"enrollment":25,"completionDate":"2010-07"},{"nctId":"NCT00811486","phase":"NA","title":"Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2009-01","conditions":["Right Heart Failure","Pulmonary Hypertension"],"enrollment":0,"completionDate":"2010-12"},{"nctId":"NCT00806910","phase":"PHASE4","title":"Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion","status":"WITHDRAWN","sponsor":"Albert Einstein Healthcare Network","startDate":"2008-10","conditions":["Heart Failure"],"enrollment":0,"completionDate":"2010-02"},{"nctId":"NCT00930202","phase":"PHASE1","title":"Study of the Safety and Efficacy of Conivaptan (Vaprisol®) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain Injury","status":"COMPLETED","sponsor":"University of Washington","startDate":"2009-08","conditions":["Severe Traumatic Brain Injury"],"enrollment":10,"completionDate":"2010-06"},{"nctId":"NCT00924014","phase":"NA","title":"Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure","status":"UNKNOWN","sponsor":"Hennepin County Medical Center, Minneapolis","startDate":"2009-07","conditions":["Heart Failure"],"enrollment":8,"completionDate":"2010-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection, Liquid, Solution","formulations":[{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"VAPRISOL DEXTROSE IN PLASTIC CONTAINER"},{"form":"LIQUID","route":"INTRAVENOUS","productName":"Vaprisol"},{"form":"SOLUTION","route":"INTRAVENOUS","productName":"Vaprisol"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000175346","MMSL":"20826","NDDF":"011178","UNII":"0NJ98Y462X","VUID":"4025087","CHEBI":"CHEBI:681850","VANDF":"4025087","INN_ID":"7947","RXNORM":"1294548","UMLSCUI":"C0966107","chemblId":"CHEMBL1755","ChEMBL_ID":"CHEMBL1755","KEGG_DRUG":"D01236","DRUGBANK_ID":"DB00872","PUBCHEM_CID":"151171","SNOMEDCT_US":"421516006","IUPHAR_LIGAND_ID":"2203","SECONDARY_CAS_RN":"210101-16-9","MESH_SUPPLEMENTAL_RECORD_UI":"C106389"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","company":"Cumberland Pharmaceuticals Inc.","brandName":"VAPRISOL DEXTROSE IN PLASTIC CONTAINER","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2005-","companyName":"Cumberland Pharms","relationship":"Original Developer"},{"period":"present","companyName":"Cumberland","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"6.7 hours","clearance":"3.0 mL/min/kg","bioavailability":"42%","fractionUnbound":"0.01%","volumeOfDistribution":"0.76 L/kg"},"publicationCount":218,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C03XA02","allCodes":["C03XA02"]},"biosimilarFilings":[],"originalDeveloper":"Cumberland Pharms","recentPublications":[{"date":"2026 Jan","pmid":"41603272","title":"Effects of arginine vasopressin deficiency on cardiac fibrosis in male Wistar rats.","journal":"Physiological reports"},{"date":"2025 Dec 22","pmid":"41428316","title":"Exploration of the protein and pharmacological landscape of monkeypox virus treatment: from entry point to end point.","journal":"Molecular diversity"},{"date":"2026 Jan 15","pmid":"41352711","title":"MEGF8-mediated GDF8 phosphorylation drives TGF-β hyperactivation in osteoarthritis cartilage degeneration: Mechanism and targeted intervention.","journal":"Life sciences"},{"date":"2025 Nov 4","pmid":"41188237","title":"Structural insights into antagonist recognition by the vasopressin V2 receptor.","journal":"Nature communications"},{"date":"2025 Nov 7","pmid":"41129740","title":"B(C(6)F(5))(3)-Catalyzed Direct Deoxygenative Alkenylation of Ketones with Pinacolborane.","journal":"The Journal of organic chemistry"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Cumberland","companyId":"cumberland","modality":"Small molecule","firstApprovalDate":"2005","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2005-12-29T00:00:00.000Z","mah":"CUMBERLAND PHARMS","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2005-12-29T00:00:00.000Z","mah":"CUMBERLAND PHARMS","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2005-12-29T00:00:00.000Z","mah":"CUMBERLAND PHARMS","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2005-12-29T00:00:00.000Z","mah":"CUMBERLAND PHARMS","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2005-12-29T00:00:00.000Z","mah":"CUMBERLAND PHARMS","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2005-12-29T00:00:00.000Z","mah":"CUMBERLAND PHARMS","brand_name_local":null,"application_number":""},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:47:03.431047+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}